#Coronavirus Disease Research #References (by AMEDEO, July 19 '25)

Antiviral Res

LEBEDIN M, Petrovsky N, Tabynov K, Tabynov K, et al
SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody.
Antiviral Res. 2025;241:106235.
PubMed Abstract available

BMJ

ARETOULI E, Malik M, Widmann C, Parker AM, et al
Cognitive and mental health outcomes in long covid.
BMJ. 2025;390:e081349.
PubMed Abstract available

Clin Infect Dis

SIZA C, Plucinski M, Lessa FC, Campelo E, et al
Antibody Response in Healthcare Workers During the Severe Acute Respiratory Syndrome Coronavirus 2 Gamma Variant Outbreak in Manaus, Brazil.
Clin Infect Dis. 2025 Jul 16:ciaf318. doi: 10.1093.
PubMed Abstract available

SHOHAM S, Dioverti MV
Combination Therapy for Protracted COVID-19: When More is More.
Clin Infect Dis. 2025 Jul 16:ciaf384. doi: 10.1093.
PubMed

LITTLE JS, Edelstein GE, Swank Z, Choudhary MC, et al
Protracted SARS-CoV-2 Infection in B-cell Depleted Patients: Immunologic andiral Characteristics and Response to Dual and Extended Antiviral Therapy.
Clin Infect Dis. 2025 Jul 16:ciaf383. doi: 10.1093.
PubMed Abstract available

Emerg Infect Dis

GURLEY ES, Plowright RK
A Roadmap of Primary Pandemic Prevention Through Spillover Investigation.
Emerg Infect Dis. 2025;31.
PubMed Abstract available

Infect Control Hosp Epidemiol

FORD JS, Wang RC, Stephenson B, Degesys NF, et al
N95((R)) filtering facepiece respirator contamination with SARS-CoV-2 following reuse and extended use.
Infect Control Hosp Epidemiol. 2025 Jul 14:1-6. doi: 10.1017/ice.2025.
PubMed Abstract available

Intensive Care Med

VAIDIE J, Demiselle J, Gabriel A, Guillon A, et al
Effect of temporary suspension of chronic immunosuppressive drugs on day-90 mortality and ICU-acquired infections among critically Ill patients with solid organ transplant: a retrospective multicenter study.
Intensive Care Med. 2025 Jul 16. doi: 10.1007/s00134-025-08024.
PubMed Abstract available

J Infect

MOOSA F, Kleynhans J, Makhathini L, du Plessis M, et al
Bordetella pertussis infection and antibody dynamics in household cohorts in two South African communities, 2016 - 2018: findings from the PHIRST study.
J Infect. 2025;91:106550.
PubMed Abstract available

J Med Virol

HUNG CT, Wang LM, Lee YJ, Suk CW, et al
Association of Nirmatrelvir/Ritonavir and the Risk of Long COVID Among US Adults: A Multicenter Retrospective Cohort Study.
J Med Virol. 2025;97:e70494.
PubMed Abstract available

KIM DH, Kim KS, Kim JH, Lim KB, et al
Cross-Species Transmission of SARS-CoV-2 From Dogs to Hamsters and Pathological Changes in the Brain.
J Med Virol. 2025;97:e70496.
PubMed Abstract available

J Virol

CARLOCK MA, Pierce SR, Ross TM
Breadth of antibody activity elicited by an influenza B hemagglutinin vaccine is influenced by pre-existing immune responses to influenza B viruses.
J Virol. 2025 Jul 15:e0070525. doi: 10.1128/jvi.00705.
PubMed Abstract available

JAMA

PRASAD V, Makary MA
US FDA Safety Labeling Change for mRNA COVID-19 Vaccines.
JAMA. 2025 Jul 14. doi: 10.1001/jama.2025.12675.
PubMed

Lancet

NEPOGODIEV D, Picciochi M, Ademuyiwa A, Adisa A, et al
Surgical health policy 2025-35: strengthening essential services for tomorrow's needs.
Lancet. 2025 Jul 14:S0140-6736(25)00985-7. doi: 10.1016/S0140-6736(25)00985.
PubMed Abstract available

Lancet Infect Dis

BROSH-NISSIMOV T
Refining COVID-19 care for immunocompromised patients.
Lancet Infect Dis. 2025 Jul 14:S1473-3099(25)00316.
PubMed

WEINSTEIN E, Paredes R, Gardner A, Almas M, et al
Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial.
Lancet Infect Dis. 2025 Jul 14:S1473-3099(25)00221.
PubMed Abstract available

OGBUAGU O, Goldman JD, Gottlieb RL, Singh U, et al
Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study.
Lancet Infect Dis. 2025 Jul 14:S1473-3099(25)00238.
PubMed Abstract available

FLAMANT A, Demirjian A, Lamagni T, Toubiana J, et al
Invasive group A streptococcal infections: lessons learned from the 2022-23 upsurge.
Lancet Infect Dis. 2025 Jul 9:S1473-3099(25)00343.
PubMed Abstract available

Science

COHEN J, Kaiser J
NIH suspends alleged 'gain-of-function' studies.
Science. 2025;389:223-224.
PubMed Abstract available

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...

ETIDIOH - NEW

Search This Blog